Recent News

• 11.04.2026 - Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
• 10.14.2026 - Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
• 09.25.2026 - Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
• 09.17.2026 - Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
• 09.01.2026 - Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
• 07.29.2026 - Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
• 07.09.2026 - Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
• 06.17.2026 - Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
• 06.15.2026 - Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
• 06.15.2026 - Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Recent Filings

• 10.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.06.2026 - 144 Report of proposed sale of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities